GlassScriptPhysician profile
John Henry Lee
NPI 1396740353
$2,949.57
in general payments reported to CMS, 2019-2025
29 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $700 · 2021: $727 · 2022: $169 · 2023: $94.94 · 2024: $143 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $412.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $381.57 | 2019-2025 | |
| Abbvie INC. | $381.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $274.66 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $215.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $183.44 | 2019-2021 | |
| Allergan, INC. | $142.16 | 2019-2020 | |
| Glaxosmithkline, LLC. | $123.93 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $119.04 | 2020-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $88.36 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $73.25 | 2021 | |
| Lilly USA, LLC | $72.74 | 2019-2021 | |
| Astellas Pharma US INC | $68.17 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.09 | 2019-2024 | Xifaxan |
| Shire North American Group INC | $47.88 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.77 | 2020-2025 | Jardiance |
| Eisai INC. | $40.42 | 2020 | |
| Amarin Pharma, INC. | $36.92 | 2019-2021 | |
| Amgen INC. | $36.53 | 2020-2025 | Evenity |
| Inspire Medical Systems, INC. | $22.57 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $18.21 | 2022 | |
| Dexcom, INC. | $17.65 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.51 | 2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $14.94 | 2019 | |
| Exact Sciences Corporation | $14.55 | 2025 | The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $14.37 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.20 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.12 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.